{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/atrial-fibrillation/prescribing-information/sotalol-not-initiated-in-primary-care/","result":{"pageContext":{"chapter":{"id":"0fae1520-f160-57a2-af90-5b46bb20bdf5","slug":"sotalol-not-initiated-in-primary-care","fullItemName":"Sotalol - not initiated in primary care","depth":2,"htmlHeader":"<!-- begin field 1a235416-b7b5-4104-af98-bf0696696166 --><h2>Sotalol - not initiated in primary care</h2><!-- end field 1a235416-b7b5-4104-af98-bf0696696166 -->","summary":"","htmlStringContent":"<!-- begin item 5e9b9478-f28f-49cd-981a-b279ea46d111 --><!-- end item 5e9b9478-f28f-49cd-981a-b279ea46d111 -->","topic":{"id":"c61747eb-a307-5da3-9878-9e952f2e1246","topicId":"e42fc175-7ae7-44c7-b7ef-b58a14733e7e","topicName":"Atrial fibrillation","slug":"atrial-fibrillation","lastRevised":"Last revised in October 2020","chapters":[{"id":"15747365-1cc2-550f-ad60-639db7df4ff0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9ced6fef-0141-5375-b1c4-37d2756e7678","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75cb268e-28e7-51c1-87dd-0a86fbc0616b","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"1390db2e-6367-52cb-9af5-792d2e4d9310","slug":"changes","fullItemName":"Changes"},{"id":"f65a3e88-8f57-5c09-867a-ba88262e838c","slug":"update","fullItemName":"Update"}]},{"id":"16591b01-3ee5-5b14-a7e2-7a5226294933","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f3967a51-562c-5a5b-b55a-02dd39bfcbe9","slug":"goals","fullItemName":"Goals"},{"id":"5a66a5f8-9497-5664-abc1-d16cfe63bdd4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ca3b265-f279-56a1-94f0-c0e96dbeaaff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8bf96582-45d8-507c-9772-4c1092b4bd6a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"992b55c8-2134-5283-b0f7-34608af53bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"677bafba-be09-57b3-a169-096ee3aa3fa1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6e491b1-6724-5c59-b127-fc29812ea52f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"dab901c7-1cc0-5253-a4e0-e5b5bc04ba5e","slug":"definition","fullItemName":"Definition"},{"id":"39c5efdc-48cc-5b0a-85d7-f7da2de67a25","slug":"causes","fullItemName":"Causes"},{"id":"211e1811-bd20-5cfb-b7b9-c06c3fd223a3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"96a3b3f8-183a-52b6-9909-a81f0fd999dd","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"fc0c1acd-3cda-53a5-85ae-be117589c6bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a1e6d67-1c9c-5ea9-a30c-006e32e641c7","slug":"diagnosis-of-atrial-fibrillation","fullItemName":"Diagnosis of atrial fibrillation"}]},{"id":"42efe54e-8ff7-5283-ad5f-7dabdd2dcdff","fullItemName":"Management","slug":"management","subChapters":[{"id":"a955511a-8fbf-5bf9-aa82-b0e634a6325b","slug":"management-of-af","fullItemName":"Scenario: Management of AF"}]},{"id":"c2a59ca9-6ff7-533b-912e-d7ba0cc5fcb9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a2c20504-f7cb-54cc-adc0-c0cb70ec0ccb","slug":"beta-blockers-except-sotalol","fullItemName":"Beta-blockers (except sotalol)"},{"id":"d02a47f9-0498-503c-9cb1-0c3f89766d4f","slug":"diltiazem-verapamil","fullItemName":"Diltiazem and verapamil"},{"id":"037e75e8-454f-5dcd-a0b8-3e9ff5a5b309","slug":"digoxin","fullItemName":"Digoxin"},{"id":"c0c53c1d-4cd9-5e70-8a01-3d5f59d213cb","slug":"anticoagulants","fullItemName":"Anticoagulants"},{"id":"49e47ec1-0743-51db-a133-a2eed45d0eb0","slug":"aspirin-clopidogrel","fullItemName":"Aspirin and clopidogrel"},{"id":"5cb461d2-9502-5698-a467-30edd459c1b3","slug":"amiodarone-not-initiated-in-primary-care","fullItemName":"Amiodarone - not initiated in primary care"},{"id":"0fae1520-f160-57a2-af90-5b46bb20bdf5","slug":"sotalol-not-initiated-in-primary-care","fullItemName":"Sotalol - not initiated in primary care"}]},{"id":"1048ec97-41b1-5f93-a54d-1f58a8a56528","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5fff0dc2-1e01-590e-a159-76736c6a2ac0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b4497d2f-172b-54a5-99c6-5cd92c8469ba","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d1d9c4e5-758a-5a99-93e3-4d2099a68d60","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0b86c2fd-54d8-569a-a8a8-ccadd53c17a0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e7ea1b2f-6198-53f7-b4f8-681296a03562","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3a114d83-bf8b-5507-b946-6af4f46c529e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5bbaf83e-cca2-55f4-a4c9-e6b808387a89","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c2a59ca9-6ff7-533b-912e-d7ba0cc5fcb9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"eaacef5e-383f-528c-a3e7-5c6894812dd6","slug":"initiation-of-sotalol","fullItemName":"Initiation of sotalol","depth":3,"htmlHeader":"<!-- begin field 2ddfed8d-cec9-448f-b709-f91594c9ec6c --><h3>How is sotalol initiated, and what is the usual maintenance dose?</h3><!-- end field 2ddfed8d-cec9-448f-b709-f91594c9ec6c -->","summary":"","htmlStringContent":"<!-- begin item 14a5cb28-2c46-45df-8259-a214bf8ee2ce --><!-- begin field 3294d909-2673-473d-952d-5292fe2de97f --><ul><li>Sotalol is usually initiated and titrated up to an appropriate dose in secondary care. However, a primary care practitioner may be expected to continue prescribing sotalol and monitor for adverse effects (depending on locally agreed shared care guidelines).</li><li>The usual maintenance dose of sotalol is 160 mg to 320 mg twice a day.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 3294d909-2673-473d-952d-5292fe2de97f --><!-- end item 14a5cb28-2c46-45df-8259-a214bf8ee2ce -->","subChapters":[]},{"id":"e37febc2-022c-5fde-83b3-ddffb6bf9415","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e53666dc-51e4-4850-8bf9-adb10b960529 --><h3>What adverse effects are associated with sotalol?</h3><!-- end field e53666dc-51e4-4850-8bf9-adb10b960529 -->","summary":"","htmlStringContent":"<!-- begin item 06950a82-f248-41e8-bce4-42ea1c8d9c3f --><!-- begin field 77d97159-ca48-405d-8c5d-c2c777151d50 --><ul><li><p>Sotalol may aggravate a pre-existing arrhythmia, provoke a new arrhythmia, or cause torsades de pointes arrhythmia (increased risk in women) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>].</p></li><li>Sotalol may also cause similar adverse effects to those of other beta-blockers. See <a class=\"topic-reference internal-reference\" href=\"/topics/atrial-fibrillation/prescribing-information/beta-blockers-except-sotalol/#adverse-effects\">Adverse effects of beta-blockers</a> for more information.</li></ul><!-- end field 77d97159-ca48-405d-8c5d-c2c777151d50 --><!-- end item 06950a82-f248-41e8-bce4-42ea1c8d9c3f -->","subChapters":[]},{"id":"5bbc53d8-aa40-54ad-ac20-9ab0f9aadb12","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field b2b443c6-0472-4b2f-b996-85c968c96e65 --><h3>What key drug interactions should I be aware of for sotalol?</h3><!-- end field b2b443c6-0472-4b2f-b996-85c968c96e65 -->","summary":"","htmlStringContent":"<!-- begin item 20a8c58f-5cc2-41a9-b747-aafdfbc485d6 --><!-- begin field fa958cd2-5587-4819-b3fa-c76146864c52 --><ul><li>Sotalol prolongs the QT interval, and only specialists should co-prescribe drugs that prolong the QT interval. This is because of the risk of additive effects, which may lead to serious and potentially life-threatening torsades de pointes arrhythmias. Examples of drugs known to have a high risk of causing QT prolongation include [<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Preston, 2016</a>] :<ul><li>Antiarrhythmics, such as amiodarone, disopyramide, and quinidine.</li><li>Antihistamines, such as astemizole and terfenadine.</li><li>Antipsychotics, such as amisulpride, haloperidol, and droperidol.</li><li>Antibiotics, such as erythromycin and clarithromycin.</li><li>Antidepressants, such as citalopram, escitalopram, clomipramine, and amitriptyline; and lithium.</li></ul></li><li>Sotalol may also interact with other drugs (in common with other beta-blockers). See <a class=\"topic-reference internal-reference\" href=\"/topics/atrial-fibrillation/prescribing-information/beta-blockers-except-sotalol/#drug-interactions\">Drug interactions with beta-blockers</a> for more information.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/atrial-fibrillation/references/\">Joint Formulary Committee, 2019</a>].</p><!-- end field fa958cd2-5587-4819-b3fa-c76146864c52 --><!-- end item 20a8c58f-5cc2-41a9-b747-aafdfbc485d6 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}